Profile

Shenzhen Salubris Pharmaceuticals Co., Ltd. founded in 1998 and listed on the Shenzhen Stock Exchange in 2009 (stock code: 002294) is an innovation-driven pharmaceutical company based in China and extended globally. The company has established a plurality of R&D centers both in China and the United States covering the whole industry chain and connecting global innovative resources to study pathogenesis, explore therapies and develop innovative drugs.

Based on patients' benefits, Salubris meets the unfulfilled clinical needs by focusing on the cardio-cerebrovascular field to develop a product system with strategic coordination of chemical medicines, biological medicines and medical devices, provides superior comprehensive solutions for patients, and explores innovative drugs in fields of hypoglycemia, anti-tumor, orthopaedics, nephropathy and anti-infection to construct the original innovation system of medicines.

With evidence-based medicine as the core, Salubris has professional marketing teams to promote innovative products to more than 30 countries and regions including China, the United States, Germany, France, Japan and so on.

The mission of "providing outstanding pharmaceutical products for human health" drives our continuous innovation.

We are committed to maintaining patient health by scientific improvement of life quality.

Eight Industry Bases

Salubris (Baoan) Medicine R&D and Industrialization Base

Salubris (Daya Bay) Oral Preparation and API Industrialization Base

Salubris (Pingshan) Medical Device and Innovative Drug Industrialization Base

Salubris (Chengdu) Biopharmaceutical R&D Base

Salubris (Suzhou) Biopharmaceutical Industrialization Base

Salubris (Shandong) Pharmaceutical Intermediate and API Industrialization Base

Salubris (Suzhou) Huanchen Medical Device Industry Base

Beijing Salubris Medtech Co.,Ltd. and Industry Base